2023
Novel engineered B lymphocytes targeting islet-specific T cells inhibit the development of type 1 diabetes in non-obese diabetic Scid mice
Chen D, Kakabadse D, Fishman S, Weinstein-Marom H, Davies J, Boldison J, Thayer T, Wen L, Gross G, Wong F. Novel engineered B lymphocytes targeting islet-specific T cells inhibit the development of type 1 diabetes in non-obese diabetic Scid mice. Frontiers In Immunology 2023, 14: 1227133. PMID: 37731505, PMCID: PMC10507356, DOI: 10.3389/fimmu.2023.1227133.Peer-Reviewed Original ResearchConceptsAntigen-specific CD8Islet-specific T cellsT cellsAutoimmune diabetesB cellsSCID miceMouse modelB lymphocytesNon-obese diabetic (NOD) mouse modelRegulatory B cell functionsProtective cell typesAntigen-specific CD4Pathogenic T cellsT cell cytotoxicityAntigen-presenting cellsCo-transfer experimentsDiabetic mouse modelDiabetic SCID miceType 1 diabetesAntigen-specific cellsB cell functionNovel therapeutic approachesMHC II moleculesSplenic B cellsPD-1
2011
Combined antibody therapy for type 1 diabetes (107.2)
Hu C, Ding H, Wong F, Wen L. Combined antibody therapy for type 1 diabetes (107.2). The Journal Of Immunology 2011, 186: 107.2-107.2. DOI: 10.4049/jimmunol.186.supp.107.2.Peer-Reviewed Original ResearchType 1 diabetesNOD miceB cellsBeneficial effectsTransgenic NOD miceDevelopment of T1D.CD4 T cellsAnti-CD3 treatmentNovel therapeutic approachesOral toleranceDiabetes preventionIL-10Antibody therapyAutoimmune diseasesPeyer's patchesT cellsTherapeutic approachesCombination treatmentMonoclonal antibodiesMiceIndividual antibodiesTregsAntibodiesCD20T1D.